Enveric Biosciences (NASDAQ:ENVB) Releases Earnings Results

Enveric Biosciences (NASDAQ:ENVB) posted its quarterly earnings data on Friday. The company reported ($0.57) earnings per share for the quarter, Zacks reports.

Enveric Biosciences Stock Down 0.3%

Shares of NASDAQ ENVB traded down $0.01 during trading hours on Friday, hitting $1.51. The company had a trading volume of 17,393 shares, compared to its average volume of 1,248,426. Enveric Biosciences has a 1-year low of $1.17 and a 1-year high of $13.25. The firm’s 50 day moving average is $1.47 and its 200-day moving average is $1.90. The stock has a market capitalization of $6.79 million, a P/E ratio of -0.12 and a beta of 1.23.

Analyst Ratings Changes

Several brokerages have issued reports on ENVB. Wall Street Zen upgraded shares of Enveric Biosciences from a “sell” rating to a “hold” rating in a research note on Sunday, August 23rd. Weiss Ratings restated a “sell (e+)” rating on shares of Enveric Biosciences in a research note on Thursday, October 15th. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the company presently has an average rating of “Sell”.

About Enveric Biosciences

Enveric Biosciences, Inc. is a biotechnology company focused on discovering and developing novel small-molecule therapeutics for cancer and central nervous system disorders. The company’s research uses insights from cannabinoid science and psychedelic-inspired compounds to identify potential treatments for conditions with significant unmet medical needs. Enveric has developed a portfolio of proprietary drug candidates and intellectual property, including programs aimed at mental health conditions such as depression and other neurological disorders, as well as therapies intended to address cancer-related symptoms and supportive-care needs.